The submission of an application for idecabtagene vicleucel comes shortly after Bristol-Myers Squibb filed for approval of another CAR-T, lisocabtagene maraleucel, in an aggressive form of lymphoma. The FDA is expected to rule on that CAR-T by February.

LEAVE A REPLY

Please enter your comment!
Please enter your name here